Author(s): Aya Ouf and Kinga Szigeti
Dementia with Lewy Bodies (DLB) is estimated to affect around 15-20% of dementia cases globally. This places it as the second most common type of dementia after Alzheimer’s disease (AD). Paradoxically, clinical trials addressing the complex symptomatology of DLB are sparse compared to AD. While substantial progress has been made in overcoming the diagnostic challenges, evidence-based treatment is elusive. In this review we summarize the available placebo-controlled clinical trials and identify areas of need to develop treatment strategies.
